Glycomine is a biotechnology company developing therapies for rare diseases, specifically targeting PMM2-CDG with its investigational drug GLM101.

Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases such as X-linked retinoschisis and Leber congenital amaurosis type 1.

AdvanCell is a clinical-stage radiopharmaceutical company developing innovative cancer therapies using targeted alpha-emitting radionuclides.

Timberlyne Therapeutics is a biopharmaceutical company developing novel therapies for autoimmune disorders, focusing on advancing a monoclonal antibody targeting CD38.